Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRV Acrivon Therapeutics	$1.30 +1.6%	$1.22	$1.05 ▼ $10.16	$40.13M	1.64	271,220 shs	121,435 shs
KPTI Karyopharm Therapeutics	$4.18 -1.4%	$4.64	$3.51 ▼ $16.95	$36.63M	0.24	85,003 shs	96,354 shs
MBIO Mustang Bio	$2.21 -7.5%	$1.44	$0.89 ▼ $24.00	$10.46M	2.16	1.61 million shs	770,839 shs
PEPG PepGen	$1.28 +3.2%	$1.40	$0.88 ▼ $19.30	$41.88M	1.16	844,204 shs	100,756 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRV Acrivon Therapeutics	+1.56%	-2.99%	+6.56%	-28.18%	-83.63%
KPTI Karyopharm Therapeutics	-1.42%	-13.10%	-7.93%	-15.56%	-72.13%
MBIO Mustang Bio	-7.53%	-28.94%	+99.10%	+66.17%	-89.08%
PEPG PepGen	+3.23%	+8.47%	-14.09%	-3.76%	-92.89%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACRV Acrivon Therapeutics	3.7408 of 5 stars	3.5	5.0	0.0	3.8	2.5	0.6
KPTI Karyopharm Therapeutics	3.9145 of 5 stars	3.4	0.0	4.6	2.9	2.5	0.6
MBIO Mustang Bio	1.1243 of 5 stars	0.0	5.0	0.0	2.8	0.0	0.6
PEPG PepGen	3.2334 of 5 stars	3.2	4.0	0.0	2.3	2.5	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACRV Acrivon Therapeutics	3.00	Buy	$17.71	1,262.64% Upside
KPTI Karyopharm Therapeutics	2.80	Moderate Buy	$37.40	794.74% Upside
MBIO Mustang Bio	0.00	N/A	N/A	N/A
PEPG PepGen	2.33	Hold	$7.67	498.96% Upside

Current Analyst Ratings Breakdown

Latest MBIO, PEPG, ACRV, and KPTI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/16/2025	KPTI Karyopharm Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
7/11/2025	KPTI Karyopharm Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$27.00
5/29/2025	PEPG PepGen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$14.00 ➝ $8.00
5/16/2025	ACRV Acrivon Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
5/15/2025	ACRV Acrivon Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$10.00 ➝ $9.00
5/13/2025	KPTI Karyopharm Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$34.00 ➝ $33.00
5/13/2025	KPTI Karyopharm Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$5.00 ➝ $10.00
5/13/2025	KPTI Karyopharm Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$54.00 ➝ $42.00
5/9/2025	PEPG PepGen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$16.00 ➝ $14.00
5/5/2025	ACRV Acrivon Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$6.00
5/4/2025	ACRV Acrivon Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACRV Acrivon Therapeutics	N/A	N/A	N/A	N/A	$5.68 per share	N/A
KPTI Karyopharm Therapeutics	$145.24M	0.25	N/A	N/A	($22.10) per share	-0.19
MBIO Mustang Bio	N/A	N/A	N/A	N/A	($2.11) per share	N/A
PEPG PepGen	N/A	N/A	N/A	N/A	$3.64 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACRV Acrivon Therapeutics	-$80.56M	-$2.22	N/A	N/A	N/A	N/A	-44.66%	-40.94%	8/12/2025 (Estimated)
KPTI Karyopharm Therapeutics	-$76.42M	-$13.26	N/A	N/A	N/A	-43.99%	N/A	-35.95%	8/5/2025 (Estimated)
MBIO Mustang Bio	-$15.75M	-$78.00	N/A	N/A	N/A	N/A	N/A	-80.79%	8/12/2025 (Estimated)
PEPG PepGen	-$89.98M	-$3.13	N/A	N/A	N/A	N/A	-81.26%	-63.65%	8/14/2025 (Estimated)

Latest MBIO, PEPG, ACRV, and KPTI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	PEPG PepGen	-$0.8150	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q2 2025	ACRV Acrivon Therapeutics	-$0.57	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	KPTI Karyopharm Therapeutics	-$3.72	N/A	N/A	N/A	$37.92 million	N/A
5/14/2025	Q1 2025	MBIO Mustang Bio	N/A	-$0.05	N/A	-$0.05	N/A	N/A
5/13/2025	Q1 2025	ACRV Acrivon Therapeutics	-$0.57	-$0.51	+$0.06	-$0.51	N/A	N/A
5/12/2025	Q1 2025	KPTI Karyopharm Therapeutics	-$4.21	-$2.77	+$1.44	-$2.77	$35.12 million	$30.02 million
5/8/2025	Q1 2025	PEPG PepGen	-$0.72	-$0.92	-$0.20	-$0.92	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACRV Acrivon Therapeutics	N/A	N/A	N/A	N/A	N/A
KPTI Karyopharm Therapeutics	N/A	N/A	N/A	N/A	N/A
MBIO Mustang Bio	N/A	N/A	N/A	N/A	N/A
PEPG PepGen	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACRV Acrivon Therapeutics	N/A	11.17	11.17
KPTI Karyopharm Therapeutics	N/A	1.33	1.28
MBIO Mustang Bio	N/A	1.34	1.34
PEPG PepGen	N/A	4.95	4.95

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACRV Acrivon Therapeutics	71.62%
KPTI Karyopharm Therapeutics	66.44%
MBIO Mustang Bio	9.95%
PEPG PepGen	58.01%

Insider Ownership

Company	Insider Ownership
ACRV Acrivon Therapeutics	11.90%
KPTI Karyopharm Therapeutics	2.98%
MBIO Mustang Bio	0.21%
PEPG PepGen	5.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACRV Acrivon Therapeutics	58	31.35 million	27.62 million	Not Optionable
KPTI Karyopharm Therapeutics	380	8.64 million	8.38 million	Optionable
MBIO Mustang Bio	100	4.38 million	4.37 million	Not Optionable
PEPG PepGen	30	32.72 million	31.02 million	Not Optionable

MBIO, PEPG, ACRV, and KPTI Headlines

Recent News About These Companies

Contact The Gross Law Firm by August 8, 2025 Deadline to Join Class Action Against PepGen Inc.(PEPG)

1 hour ago | prnewswire.com

PEPGEN ALERT: Bragar Eagel & Squire, P.C. Urges Investors in PepGen, Inc. (PEPG) to Inquire About Their Rights in Class Action Lawsuit

July 16 at 7:14 PM | globenewswire.com

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of PepGen

July 16 at 11:40 AM | globenewswire.com

PepGen Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before August 8, 2025 to Discuss Your Rights â€“ PEPG

July 16 at 9:20 AM | globenewswire.com

PEPG Investors Have Opportunity to Lead PepGen Inc. Securities Fraud Lawsuit with the Schall Law Firm

July 16 at 5:14 AM | prnewswire.com

PEPG INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that PepGen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

July 15 at 4:00 PM | globenewswire.com

ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages PepGen Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PEPG

July 15 at 1:03 PM | globenewswire.com

Faruqi & Faruqi Reminds PepGen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 11, 2025 - PEPG

July 15 at 10:13 AM | prnewswire.com

Class Action Filed Against PepGen Inc. (PEPG) Seeking Recovery for Investors - Contact Levi & Korsinsky

July 15 at 9:00 AM | prnewswire.com

PEPGEN INC. (NASDAQ: PEPG) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds PepGen Inc.

July 14 at 9:22 PM | reflector.comR

Lost Money on PepGen Inc.(PEPG)? Join Class Action Suit Seeking Recovery â€“ Contact Levi & Korsinsky

July 14 at 5:04 PM | globenewswire.com

PEPG Investors Have Opportunity to Lead PepGen Inc. Securities Fraud Lawsuit

July 14 at 1:53 PM | prnewswire.com

PEPGEN INC. (NASDAQ: PEPG) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds PepGen Inc. Investors of Upcoming Deadline

July 14 at 10:42 AM | globenewswire.com

PEPG Investors Have Opportunity to Lead PepGen Inc. Securities Fraud Lawsuit with the Schall Law Firm

July 14 at 10:23 AM | prnewswire.com

Contact The Gross Law Firm by August 8, 2025 Deadline to Join Class Action Against PepGen Inc.(PEPG)

July 14 at 9:00 AM | prnewswire.com

PepGen Inc. Sued for Securities Law Violations - Morningstar

July 12, 2025 | morningstar.comM

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages PepGen Inc. Investors to Secure Counsel Before ...

July 12, 2025 | bakersfield.comB

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages PepGen Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PEPG

July 12, 2025 | globenewswire.com

Pomerantz Law Firm Announces the Filing of a Class Action Against PepGen Inc. and Certain Officers - PEPG

July 12, 2025 | prnewswire.com

PepGen Inc. Class Action: Levi & Korsinsky Reminds PepGen Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 8, 2025 – PEPG

July 11, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MBIO, PEPG, ACRV, and KPTI Company Descriptions

Acrivon Therapeutics NASDAQ:ACRV

$1.30 +0.02 (+1.56%)

Closing price 07/16/2025 04:00 PM Eastern

Extended Trading

$1.34 +0.03 (+2.69%)

As of 09:13 AM Eastern

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.

Karyopharm Therapeutics NASDAQ:KPTI

$4.18 -0.06 (-1.42%)

Closing price 07/16/2025 04:00 PM Eastern

Extended Trading

$4.31 +0.13 (+3.11%)

As of 08:20 AM Eastern

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Mustang Bio NASDAQ:MBIO

$2.21 -0.18 (-7.53%)

Closing price 07/16/2025 04:00 PM Eastern

Extended Trading

$2.19 -0.02 (-0.90%)

As of 09:15 AM Eastern

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-101 CAR T cell program for glioblastoma; MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.

PepGen NASDAQ:PEPG

$1.28 +0.04 (+3.23%)

Closing price 07/16/2025 04:00 PM Eastern

Extended Trading

$1.28 +0.00 (+0.39%)

As of 08:56 AM Eastern

PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time